Inmed pharmaceuticals announces $5 million private placement priced at-the-market under nasdaq rules

Vancouver, british columbia--(newsfile corp. - june 25, 2025) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-term preferred investment option in a private placement priced at-the-market under nasdaq rules. the short-term preferred investment option to be issued in the offering will be exercisable immediately upon issuance at an exercise price of $2.436 per share and will expire eighteen months from the effective date of the resale registration statement (as defined below).
INM Ratings Summary
INM Quant Ranking